Oral delivery of alloantigen combined with non-depleting anti-CD4 monoclonal antibody induces indefinite survival of cardiac allografts and generates CD4(+) regulatory T cells.
Niimi
M
M
1st Department of Surgery, Teikyo University, Tokyo, Japan.
Ikeda
Y
Y
Shirasugi
N
N
Shatari
T
T
Takami
H
H
Kodaira
S
S
Matsumoto
K
K
Hamano
K
K
Esato
K
K
Hara
M
M
Wood
K J
KJ
D000284:Administration, Oral; D019264:Adoptive Transfer; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D015704:CD4 Antigens / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D006085:Graft Survival / Q000276:immunology*; D016027:Heart Transplantation / Q000276:immunology* / Q000502:physiology; D007165:Immunosuppression Therapy / Q000379:methods*; D007519:Isoantigens / Q000008:administration & dosage / Q000276:immunology*; D017710:Lymphocyte Transfusion; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D008822:Mice, Transgenic; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D007519:Isoantigens